US 11,730,756 B2
Method of administration and treatment
Ryan Beal, Thousand Oaks, CA (US)
Assigned to Dyve Biosciences, Inc., Camarillo, CA (US)
Filed by DYVE BIOSCIENCES, INC., Thousand Oaks, CA (US)
Filed on Feb. 4, 2021, as Appl. No. 17/168,114.
Application 16/866,466 is a division of application No. 16/546,256, filed on Aug. 20, 2019, granted, now 10,639,326.
Application 16/546,256 is a division of application No. 16/132,358, filed on Sep. 14, 2018, abandoned.
Application 16/132,358 is a division of application No. 16/132,357, filed on Sep. 14, 2018, abandoned.
Application 17/168,114 is a continuation of application No. 16/866,466, filed on May 4, 2020, granted, now 10,933,088.
Application 16/132,357 is a continuation in part of application No. PCT/US2018/028017, filed on Apr. 17, 2018.
Claims priority of provisional application 62/639,904, filed on Mar. 7, 2018.
Claims priority of provisional application 62/609,982, filed on Dec. 22, 2017.
Claims priority of provisional application 62/562,725, filed on Sep. 25, 2017.
Claims priority of provisional application 62/559,947, filed on Sep. 18, 2017.
Claims priority of provisional application 62/559,360, filed on Sep. 15, 2017.
Prior Publication US 2021/0154226 A1, May 27, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 33/00 (2006.01); A61K 31/198 (2006.01); A61K 31/4172 (2006.01); A61K 31/133 (2006.01); A61K 9/00 (2006.01); A61K 35/00 (2006.01); A61K 9/16 (2006.01); A61K 33/42 (2006.01); A61P 35/04 (2006.01); A61K 31/704 (2006.01); A61K 39/395 (2006.01); A61K 31/661 (2006.01); A61K 9/06 (2006.01); A61K 31/045 (2006.01); A61K 31/685 (2006.01); A61K 33/30 (2006.01); C07K 16/28 (2006.01); A61K 9/70 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01); A61K 47/24 (2006.01); A61K 39/00 (2006.01)
CPC A61K 33/00 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/16 (2013.01); A61K 9/7023 (2013.01); A61K 31/045 (2013.01); A61K 31/133 (2013.01); A61K 31/198 (2013.01); A61K 31/4172 (2013.01); A61K 31/661 (2013.01); A61K 31/685 (2013.01); A61K 31/704 (2013.01); A61K 33/30 (2013.01); A61K 33/42 (2013.01); A61K 35/00 (2013.01); A61K 39/3955 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/22 (2013.01); A61K 47/24 (2013.01); A61P 35/04 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01)] 20 Claims
 
1. A method of treating a gout, comprising administering a transdermal formulation comprising a buffering agent, wherein the transdermal formulation comprising the buffering agent is administered to a patient having abnormal levels of uric acid crystals in one or more joints, tendons or surrounding tissue, and wherein the buffering agent reduces the levels of uric acid crystals in the one or more joints, tendons or surrounding tissue of said patient, resulting in a reduction in the symptoms of the a gout, wherein the buffering agent consists of sodium bicarbonate.